Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by wizzdumbon Dec 15, 2024 4:36pm
92 Views
Post# 36363318

RE:Target price $0.80

RE:Target price $0.80Yeah and that's just the current core business with some pretty conservative growth baked in. Add in Kinlytic for just the current indication and geography that was partnered and that's another buck. That partnership will be expanded for the current indication to other geographies and for new indications and geographies in due course, but not until the new drug manufacturing is approved, which is extremely low risk. If I gave my thoughts on what the new indications and geographies could be worth probably only a very few here would even know what I was talking about and the rest would laugh me out of the room, but it will come.  
<< Previous
Bullboard Posts
Next >>